Home Integrity Applications Inc.

Integrity Applications, GlucoTrack® Innovator, Names David Podwalski as Chief Commercial Officer

Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels in people with type 2 diabetes and prediabetes, today announced the appointment of David Podwalski as Chief Commercial Officer.

The company reports that Mr. Podwalski is a seasoned pharmaceutical and life sciences executive with more than 20 years of experience in global commercial leadership, most notably with insulin-based therapies. Most recently, he served at Ernst & Young as Senior Consultant and Subject Matter Expert, Life Sciences, where he assisted major pharmaceutical, animal health, diagnostic, and medical device companies in developing innovative go-to-market commercial strategies, sales and marketing excellence programs, product launch roadmaps, commercial operations and analytics support, and enhanced patient and physician support services.

Previously, Mr. Podwalski was Senior Director of Global Commercial Effectiveness at Aventis Pharmaceuticals, where he designed and established leading practices in sales and marketing capabilities in the US, Europe, Asia and Latin America. While at Aventis, Mr. Podwalski provided global commercial leadership in the development of the global insulin business and improved pen delivery systems. Mr. Podwalski successfully launched Lantus and the Insulin Pen Delivery system in the United States, Germany, Japan and multiple other countries. This innovative basal insulin achieved peak sales of more than $9 billion, and has cumulative sales of more than $65 billion. Earlier in his career, Mr. Podwalski served in various capacities at Hoechst Marion Roussel Inc., including senior commercial leadership positions in both pharmaceutical and consumer healthcare products, most notably in diabetes.

John Graham, CEO and Chairman of Integrity Applications, remarked, “We are excited to have David join the Integrity Applications’ team. His extensive commercial and marketing background in diabetes, including driving sales and marketing for numerous new and relaunched products in the medical device industry, will be advantageous as we prepare to expand GlucoTrack commercial initiatives and implement strategies to capture a substantial portion of the market for non-invasive glucose monitoring in prediabetes and type 2 diabetes.”

“I am pleased to be joining Integrity Applications at such an exciting time in the company’s growth. We are seeing the convergence of glucose monitoring technology and digital health for diabetes, and I am enthusiastic about the commercial opportunities for GlucoTrack. There is an urgent need to transform diabetes management and to slow the progression of the diabetes epidemic. We believe that GlucoTrack, a non-invasive and patient-friendly approach to glucose monitoring, has significant potential in these large and clinically important markets,” replied Podwalski.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version